All in all, our results suggest that 4Mu exerts a significant antitumoral effect: (i) by inducing a switch of hepatic Mφ into a M1 profile, (ii) by reducing their capacity to secrete IL-6, (iii) by increasing HCC recognition by the immune system upon incubation of tumor cells with CM derived from Mφ treated with 4Mu; (iv) by reducing the expression of several CSCs markers on HCC cells; and (v) by increasing the ability of DCs to inhibit HCC tumor growth in therapeutic vaccination protocols. This evidence concerns the gene IL6 and hepatocellular carcinoma.